Integra LifeSciences Holdings

Day range

$12.00 – $12.24

Open

$12.05

Prev close

$11.91

Volume

436.44K

Market cap

$926.27M

Shares out

77.77M

P/E

71.18

P/S

0.56

P/B

0.87

P/FCF

10.80

ROE

1.2%

ROA

0.4%

Debt/Equity

1.71

Div yield

0.00%

As of Oct 23, 2026

• Guidance issuance or updateOct 21, 2026

  In the Press Release, the Company provided forward-looking guidance regarding organic revenues and adjusted earnings per diluted share but did not provide reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort.

• Deal terminationOct 19, 2026

  The Existing Credit Agreement... was repaid in full... and the revolving commitments thereunder were terminated. The Company did not incur any early termination penalties in connection with the repayment of the Existing Credit Agreement.

• Debt issuanceOct 9, 2026

  On October 9, 2026, Integra LifeSciences Holdings Corporation issued a press release announcing the pricing of $450 million aggregate principal amount of 9.500% senior secured notes due 2033 (the "Notes") in a private placement.

• Preliminary resultsOct 2, 2026

  On October 2, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced certain preliminary unaudited results for the third quarter ended September 30, 2026. The Company expects its reported revenue to be between $410 million to $412 million... The Company expects its adjusted earnings per diluted share for the third quarter to be between $0.55 to $0.59. In addition, the Company expects operating cashflow to be greater than $85 million in the third quarter.

• Investor presentationSep 8, 2026

  Integra LifeSciences Holdings Corporation (the "Company") hereby furnishes the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use, from time to time, in presentations to existing or prospective lenders in connection with the Company's previously-disclosed plans to refinance its outstanding senior credit facility in 2026.

Days to cover

7.5

Short interest

7.27M

Avg volume

967.95K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Integra: 3 Key Takeaways for Long-Term Investors
  neutralThe Motley Fool· Oct 21, 2026
• Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates
  neutralZacks Investment Research· Oct 21, 2026
• Integra LifeSciences Reports Third Quarter 2026 Financial Results
  neutralGlobeNewswire Inc.· Oct 21, 2026
• Stock Market Midday, Oct. 2: Stocks Rally as Weak Jobs Data Cools Fed Rate Hike Bets
  positiveThe Motley Fool· Oct 2, 2026
• IART vs. PEN: Which Stock Is the Better Value Option?
  positiveZacks Investment Research· Oct 1, 2026